Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/309% above fair value
$5.94−0.08 (-1.33%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Ocular Therapeutix operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ocular Therapeutix's operating income for the twelve months ending Jun 30, 2026 was -$313.91M. For fiscal 2025 it was -$270.02M. The highest annual figure on record is -$12.90M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$270.02M | – |
| FY2024 | Dec 31, 2024 | -$171.78M | – |
| FY2023 | Dec 31, 2023 | -$82.38M | – |
| FY2022 | Dec 31, 2022 | -$78.65M | – |
| FY2021 | Dec 31, 2021 | -$78.04M | – |
| FY2020 | Dec 31, 2020 | -$62.85M | – |
| FY2019 | Dec 31, 2019 | -$85.80M | – |
| FY2018 | Dec 31, 2018 | -$59.12M | – |
| FY2017 | Dec 31, 2017 | -$61.92M | – |
| FY2016 | Dec 31, 2016 | -$43.33M | – |
| FY2015 | Dec 31, 2015 | -$38.20M | – |
| FY2014 | Dec 31, 2014 | -$27.09M | – |
| FY2013 | Dec 31, 2013 | -$12.90M | – |
| FY2012 | Dec 31, 2012 | -$13.67M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$82.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -$93.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$68.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$67.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$63.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$50.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$43.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.21M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.55M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.53M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.14M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.60M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.28M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.82M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.56M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.46M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.20M | – |
| Q2 FY2017 | Jun 30, 2017 | -$18.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.67M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.47M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.24M | – |
See a number that looks wrong?